Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape
Fangqiang Zhu(Lawrence Livermore National Laboratory), Daniel Faissol(Lawrence Livermore National Laboratory), Svetlana A. Hopkins(Logistics Management Institute (United States)), Christopher Morehouse, Joseph R. Francica(National Institute of Allergy and Infectious Diseases), Thomas J. D. Bates(Lawrence Livermore National Laboratory), Christopher G. Earnhart(United States Department of Defense), Conor F. Hayes(Lawrence Livermore National Laboratory), Edmond Y. Lau(Lawrence Livermore National Laboratory), Kevin M. Tuffy(Penn State Milton S. Hershey Medical Center), Gilad Kaplan(AstraZeneca (Japan)), Pavlo Gilchuk(AstraZeneca (Japan)), Aiste Dijokaite-Guraliuc(Centre for Human Genetics), Yíngyún Caì(National Institutes of Health), Benjamin Sparklin(AstraZeneca (Poland)), Drew Bennett(Lawrence Livermore National Laboratory), Felipe Leno da Silva(Lawrence Livermore National Laboratory), Brenden K. Petersen(Lawrence Livermore National Laboratory), Jagadish Beloor(AstraZeneca (Poland)), Juthathip Mongkolsapaya(Centre for Human Genetics), Brent W. Segelke(Lawrence Livermore National Laboratory), Andrew Dippel(AstraZeneca (Japan)), Mikel Landajuela(Lawrence Livermore National Laboratory), Saravanan Rajan(AstraZeneca (Japan)), Simone Conti(Lawrence Livermore National Laboratory), Gustavo H. Kijak(Walter Reed Army Institute of Research), Kathryn T. Arrildt(Lawrence Livermore National Laboratory), Mark T. Esser(AstraZeneca (United States)), Vancheswaran Gopalakrishnan(AstraZeneca (United States)), Adam Zemła(Lawrence Livermore National Laboratory), Emilia A. Grzesiak(Lawrence Livermore National Laboratory), Thomas Desautels(Lawrence Livermore National Laboratory), Gavin Screaton(University of Oxford), Chang Liu(Paul Scherrer Institute), Yi Zhang(National Institutes of Health), Shivshankar Sundaram(Lawrence Livermore National Laboratory), Ka Yin Kwong(AstraZeneca (Japan)), Amy Nguyen(AstraZeneca (Poland)), John W. Goforth(Lawrence Livermore National Laboratory), Bismark Amofah(AstraZeneca (Japan)), André Gonçalves(Lawrence Livermore National Laboratory), Vanessa Cadevilla Peano(AstraZeneca (Poland)), Michael Kierny(AstraZeneca (Japan))
Cited by 6